Elutia (ELUT) Competitors

Elutia (NASDAQ:ELUT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Is ELUT or PRTC more profitable?

PureTech Health has a net margin of 0.00% compared to Elutia's net margin of -218.72%.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	-218.72%	N/A	-142.61%
PureTech Health	N/A	N/A	N/A

Does the media refer more to ELUT or PRTC?

In the previous week, Elutia had 5 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Elutia and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.93 beat Elutia's score of 0.75 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, ELUT or PRTC?

Elutia has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$24.38M	4.41	-$37.66M	-$2.47	-1.07
PureTech Health	$3.33M	139.50	-$65.70M	N/A	N/A

Which has more risk and volatility, ELUT or PRTC?

Elutia has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Do insiders & institutionals believe in ELUT or PRTC?

74.0% of Elutia shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 40.8% of Elutia shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate ELUT or PRTC?

Elutia currently has a consensus price target of $9.00, suggesting a potential upside of 240.91%. PureTech Health has a consensus price target of $45.00, suggesting a potential upside of 132.68%. Given Elutia's higher possible upside, equities research analysts clearly believe Elutia is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Does the MarketBeat Community favor ELUT or PRTC?

Elutia received 2 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 100.00% of users gave Elutia an outperform vote while only 45.00% of users gave PureTech Health an outperform vote.

Company	Underperform	Outperform
Elutia	Outperform Votes 11 100.00%	Underperform Votes No Votes
PureTech Health	Outperform Votes 9 45.00%	Underperform Votes 11 55.00%

Summary

Elutia beats PureTech Health on 9 of the 16 factors compared between the two stocks.